Putting patients first.
Advancing the future of rare disease treatment.
Throughout my career as a researcher, I have had the opportunity to hear directly from patients living with rare diseases and from the families who support them. Those experiences continue to shape how we approach our work and remain an important guide as we move forward.
Since our founding, we have pursued R&D with the courage to take a step forward, building pioneering expertise in biopharmaceuticals. The technologies and knowledge we have accumulated now form the foundation of our distinctive capabilities in rare disease research. Because these areas present complex challenges, they are also where our strengths can make a meaningful difference. By advancing our pipeline and expanding our proprietary technologies, we aim to deliver new treatment options while achieving sustainable growth.
At the same time, we continue to value the venture spirit that has defined JCR since its earliest days. Our willingness to challenge the unknown and adapt to change enables us to take on difficult areas of medicine.
Many patients and families are still waiting for treatments that remain out of reach. To help change that reality, we will continue to dedicate ourselves to advancing treatments for rare diseases and pursue new possibilities. Through these efforts, we aim to deepen society’s trust in JCR while enhancing our long term corporate value.
April, 2026
Representative Director, President, Chief Scientific Officer
Hiroyuki Sonoda, Ph.D.
